Investigating a new treatment for spinal cord injuries using a specific antibody therapy.
Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment
This study is testing a new treatment called VersaMab-101 to help people with spinal cord injuries by encouraging the growth of damaged nerve cells and improving their recovery.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versapeutics INC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10821556 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy for spinal cord injuries (SCI) using an antibody called VersaMab-101. The approach aims to promote the regeneration of damaged nerve cells by overcoming barriers that prevent axon growth at the injury site. By targeting specific interactions that inhibit recovery, the therapy seeks to restore neural circuits and improve functional outcomes for patients. The study will involve preclinical testing to evaluate the safety and effectiveness of this treatment before it can be considered for human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have experienced acute spinal cord injuries.
Not a fit: Patients with chronic spinal cord injuries or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves recovery and quality of life for individuals with spinal cord injuries.
How similar studies have performed: While there have been various approaches to spinal cord injury treatment, this specific method using antibody therapy is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
San Diego, United States
- Versapeutics INC — San Diego, United States (Active)
Researchers
- Principal investigator: Sun, Miao — Versapeutics INC
- Study coordinator: Sun, Miao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.